Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes

References

• Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-l β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity20(3), 319–325 (2004).
   PubMed Web of Science ®Google Scholar
• Kile RL, Rusk HA. A case of cold urticaria with an unusual family history. JAMA114, 1067–1068 (1940).
   Google Scholar
• Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologics. Springer Semin. Immunopathol.27(4), 494–508 (2006).
   PubMed Web of Science ®Google Scholar
• Muckle T, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q. J. Med.31235–31248 (1962).
   Google Scholar
• Lorber J. Syndrome for diagnosis: dwarfing, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc. R. Soc. Med.66(11), 1070–1071 (1973).
   PubMedGoogle Scholar
• Kummer JA, Broekhuizen R, Everett H et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J. Histochem. Cytochem.55(5), 443–452 (2007).
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell10(2), 417–426 (2002).
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature440(7081), 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Cassel SL, Eisenbarth SC, Iyer SS et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA105(26), 9035–9040 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Muruve DA, Petrilli V, Zaiss AK et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature452(7183), 103–107 (2008).
   PubMed Web of Science ®Google Scholar
• Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ.14(9), 1583–1589 (2007).
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Lowe P, Felix SD et al.In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes. J. Exp. Med.206(5), 1029–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N. Engl. J. Med.348(25), 2583–2584 (2003).
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med.355(6), 581–592 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum.58(8), 2443–2452 (2008).
   PubMed Web of Science ®Google Scholar
• Dode C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle–Wells syndrome (MWS) and renal amyloidosis. J. Nephrol.16(3), 435–437 (2003).
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Lovell DJ. Recognition of infantile-onset multisystem inflammatory disease as a unique entity. J. Pediatr.130(4), 513–515 (1997).
   PubMed Web of Science ®Google Scholar
• Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1b in inflammatory disorders. Nat. Clin. Pract. Rheumatol.4(1), 34–42 (2008).
   PubMedGoogle Scholar
• Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum.50(8), 2708–2709 (2004).
   PubMedGoogle Scholar
• Hoffman HM, Rosengren S, Boyle DL et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet364(9447), 1779–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol.142(12), 1591–1597 (2006).
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Stirnemann J, Caux F et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle–Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford)47(3), 309–310 (2008).
   PubMed Web of Science ®Google Scholar
• Mirault T, Launay D, Cuisset L et al. Recovery from deafness in a patient with Muckle–Wells syndrome treated with anakinra. Arthritis Rheum.54(5), 1697–1700 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connell SM, O’Regan GM, Bolger T et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr. Dermatol.24(1), 85–89 (2007).
   PubMed Web of Science ®Google Scholar
• Ross JB, Finlayson LA, Klotz PJ et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J. Cutan. Med. Surg.12(1), 8–16 (2008).
   PubMed Web of Science ®Google Scholar
• Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle–Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis.65(4), 533–534 (2006).
   PubMed Web of Science ®Google Scholar
• Neven B, Marvillet I, Terrada C et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum.62(1), 258–267 (2010).
   PubMed Web of Science ®Google Scholar
• Miyamae T, Inaba Y, Nishimura G et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr. Rheumatol. Online J.8, 9 (2010).
   PubMed Web of Science ®Google Scholar
• Ratner M. IL-1 trap go-ahead. Nat. Biotechnol.26(5), 485 (2008).
   PubMedGoogle Scholar
• Goldbach-Mansky R, Shroff SD, Wilson M et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum.58(8), 2432–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Hashkes P, Lovell D, Giannini E, Huang B, Kastner D. Rilonacept (IL-1 trap) for treatment of colchicine resistant familial mediterranean fever: a randomized, multicenter double-blinded, alternating treatment (n of 1) trial. Clin. Exp. Rheumatol.26(2), 193 (2008).
   Web of Science ®Google Scholar
• Lovell D, Giannini E, Kimura Y et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Ann. Rheum. Dis.65(Suppl. 2), 693 (2006).
   Google Scholar
• Lovell DJ, Giannini EH, Kimura Y et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum.54(9), S325–S326 (2006).
   PubMed Web of Science ®Google Scholar
• Radin A, Terkeltaub R, Schumacher H et al. Placebo-controlled pilot study of rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Clin. Exp. Rheumatol.26(2), 181–181 (2008).
   Web of Science ®Google Scholar
• Terkeltaub R, Schumacher HR, Sundy J et al. Placebo-controlled pilot study of rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Arthritis Rheum.56(12), 4231–4232 (2007).
   Google Scholar
• Novartis preclinical research day. Novartis AG Company Presentation. 3 May 2005.
   Google Scholar
• Investor relations: pharmaceutical pipeline event. Novartis AG company presentation. 20 September 2005.
   Google Scholar
• Cook GP, Savic S, Wittmann M, McDermott MF. The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur. J. Immunol.40(3), 631–634 (2010).
   PubMed Web of Science ®Google Scholar
• Fishwild DM, O’Donnell SL, Bengoechea T et al. High-avidity human IgG κ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol.14(7), 845–851 (1996).
   PubMed Web of Science ®Google Scholar
• Bonner J, Lloyd P, Lowe P, Golor G, Woessner R, Pascoe S. PK/PD, safety and tolerability of a human anti-IL-1β monoclonal antibody (ACZ885) in healthy subjects. Presented at: 16th Annual Congress of the European Respiratory Society. Munich, Germany, 2–6 September 2006 (Abstract 748).
   Google Scholar
• Alten R, Gram H, Joosten LA et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res.Ther.10(3), R67 (2008).
   PubMed Web of Science ®Google Scholar
• Alten R, Pohl C, Batard Y et al. ACR 20/50/70 responses in methotrexate(MTX)-resistent rheumatoid arthritis (RA) patients in a double-blind, placebo (PBO)-controlled Phase I/II evaluation of the pharmacokinetics/pharmacodynamics (PK/PD), safety, and preliminary efficacy of a fully human anti interleukin 1 antibody. Ann. Rheum. Dis.67(Suppl. 2), OP0178 (2007).
   Google Scholar
• Gattorno M, Tassi S, Carta S et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum.56(9), 3138–3148 (2007).
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med.360(23), 2416–2425 (2009).
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tzaribachev N, Hausmann S et al. Long-lasting response to ACZ885 (a new human IgG1 anti-IL-1β monoclonal antibody) in patients with Muckle–Wells syndrome (MWS). Clin. Exp. Rheumatol.26(2), 180 (2008).
   Web of Science ®Google Scholar
• Lachmann HJ, Jung T, Bobadilla M et al. Treatment of Muckle–Wells syndrome with a fully human anti-IL-1β monoclonal antibody (ACZ885) – initial results from a proof of concept study. Ann. Rheum. Dis.65(Suppl. 2), 76 (2006).
   Web of Science ®Google Scholar
• Lachmann H, Jung T, Felix S et al. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1β monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin. Exp. Rheumatol.26(2), 181 (2008).
   Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tzaribachev N, Hansmann S et al. Long lasting response to ACZ885 in patients with Muckle–Wells syndrome (MWS). Ann. Rheum. Dis.67(Suppl. 2), 104 (2008).
   Google Scholar
• Kuemmerle-Deschner JB, Blank N, Roesdler J et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody provides long-lasting remission in children with cryopyrin asociated periodic syndromes (CAPS). Arthritis Rheum.58(9 Suppl.), S633 (2008).
   Google Scholar
• Ruperto N, Quartier P, Wulffraat N et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody has a beneficial effect in children with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum.58(9 Suppl.), S942–S943 (2008).
   Google Scholar
• Ruperto N, Quartier P, Wulffraat N et al. A Phase II trial with canakinumab, a new IL-1β blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic juvenile idiopathic arthritis (SJIA). Paediatr. Rheumatol. Online J.6(Suppl. 1), S2 (2008).
   PubMedGoogle Scholar
• Pascoe S, Kanniess F, Bonner J et al. A monoclonal antibody to IL-1β attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Presented at: 16th Annual Congress of the European Respiratory Society. Munich, Germany, 2–6 September 2006 (Abstract 752).
   Google Scholar
• Kuemmerle-Deschner JB, Blank N, Roesler J et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome. Paediatr. Rheumatol. Online J.6(Suppl. 1), S26 (2008).
   Google Scholar
• Allantaz F, Chaussabel D, Stichweh D et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med.204(9), 2131–2144 (2007).
   PubMed Web of Science ®Google Scholar
• Buch M, Bingham S, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor a blockade. Arthritis Rheum.50(3), 725–728 (2004).
   PubMed Web of Science ®Google Scholar